CD Laboratory for next-level biopharmaceuticals in E. coli
Abstract
The vision of this research project is to make Escherichia coli the production system of choice for next-level biopharmaceuticals. To discover, develop, and deliver scientific solutions for efficient production of challenging recombinant proteins with E. coli. The CD laboratory will unite the scientific expertise of university and company research groups focusing on topics along the process chain. Experts in molecular biology, fermentation, downstream processing, and protein analytics jointly elaborate a fundamental and integrated systems knowledge database for development of rational and integrated systems engineering concepts. The project will focus on two research fields: Systems characterization and design: Antibody fragments and new scaffolds are selected as representatives for next-level pharmaceuticals. The host cell response to expression of demanding proteins under specified process operation conditions will be analyzed with a broad spectrum of modern analytical techniques. In parallel translation, translocation, localization, periplasmic folding and degradation of recombinant proteins will be investigated in detail by employing specially designed model proteins and/or mutant strains. Improved fundamental understanding of E. coli cell factories will allow for rational host design dedicated to overcome cellular bottlenecks limiting overall process performance. Integrated up- and downstream processing: Goal is to establish an integrated approach allowing for perfect harmonization of all individual steps of the process chain to gain highest product quality and quantity. The influence of variation in specific process sections on subsequent units and product quality will be investigated and the thus acquired understanding of interrelations will be integrated in optimization strategies. In process engineering concerted design of innovative fermentation and product recovery strategies for periplasmic recombinant proteins will be followed. Special focus will be laid on micro-particle technology representing a new downstream approach. The company partner Boehringer Ingelheim is a research-driven group of companies dedicated to research, developing, manufacturing and marketing pharmaceuticals that improve health and quality of life. Research & development has been the foundation of Boehringer Ingelheim's success and continues to be the major driver of innovative, new medicines for the treatment of diseases with an unmet therapeutic need. Boehringer Ingelheim BioXcellence™ (Vienna, Austria) is a world-leading biopharmaceutical contract manufacturer. To hold and further develop this position a strong innovation line is needed which can only be achieved by joint academic and industrial research activities.
antibody fragments process integration micro particle based cell extraction E.coli recombinant protein production
Publikationen
Production of antibody fragments with plasmid-based and genome integrated T7 E.coli expression systems - evaluation of systems performance in microtiter fed-batch like cultivations
Autoren: Cserjan, M; Fink, M; Vazulka, S; Egger, E; Tauer, C; Jarmer, J; Striedner, G; Jahr: 2018
Conference & Workshop proceedings, paper, abstract
Bioprocess control: Deeper insights into LacI autoregulation and how to exploit it
Autoren: Schuller, A; Cserjan, M; Jarmer, J; Wagenknecht, M; Reinisch, D; Grabherr, R; Striedner, G Jahr: 2019
Conference & Workshop proceedings, paper, abstract
Bioprocess control: Deeper insights into LacI autoregulation and how to exploit it
Autoren: Schuller, A; Cserjan, M; Jarmer, J; Wagenknecht, M; Reinisch, D; Grabherr, R; Striedner; G Jahr: 2019
Conference & Workshop proceedings, paper, abstract
Project staff
Gerald Striedner
Univ.Prof. Dr. Gerald Striedner
gerald.striedner@boku.ac.at
Tel: +43 1 47654-79077
Project Leader
01.10.2016 - 30.04.2024
Monika Cserjan
Dipl.-Ing. Dr. Monika Cserjan
monika.cserjan@boku.ac.at
Tel: +43 1 47654-79096
Project Staff
01.10.2016 - 20.03.2017
Project Staff
21.03.2017 - 30.09.2023
Mathias Fink
Dipl.-Ing. Dr.rer.nat. Mathias Fink B.Sc.
mathias.fink@boku.ac.at
Tel: +43 1 47654-79081
Project Staff
01.10.2016 - 30.04.2024
Reingard Grabherr
Univ.Prof. Dipl.-Ing. Dr.rer.nat. Reingard Grabherr
reingard.grabherr@boku.ac.at
Tel: +43 1 47654-79856
Project Staff
01.10.2016 - 30.04.2024
Rainer Hahn
Assoc. Prof. Dipl.-Ing. Dr. Rainer Hahn
rainer.hahn@boku.ac.at
Tel: +43 1 47654-79094
Sub Projectleader
01.10.2016 - 30.04.2024
Esther Egger
Mag. Esther Egger
esther.egger@boku.ac.at
Tel: +43 1 47654-79890
Project Staff
01.10.2016 - 30.04.2024
Stephan Gutmann
Stephan Gutmann MSc.
stephan.gutmann@boku.ac.at
Tel: +43 1 47654-79863
Project Staff
01.10.2016 - 30.04.2024
Marco Klanschnig
Marco Klanschnig MSc.
marco.klanschnig@boku.ac.at
Tel: +43 1 47654-79877
Project Staff
01.10.2016 - 30.04.2024
Lisa Letschnig
Lisa Letschnig
lisa.letschnig@students.boku.ac.at
Project Staff
01.10.2016 - 30.04.2024
Florian Mayer
Dipl.-Ing. Florian Mayer
Project Staff
01.10.2016 - 30.10.2017
Project Staff
01.10.2016 - 30.04.2024
Corinna Schödl
Corinna Schödl
corinna.schoedl@students.boku.ac.at
Project Staff
01.10.2016 - 30.04.2024
Andreas Weber
Dipl.-Ing. Dr. Andreas Weber
andreas.weber@boku.ac.at
Project Staff
01.10.2016 - 30.04.2024
BOKU partners
External partners
Boehringer Ingelheim Austria GmbH
none
partner